Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | MSH6 negative |
| Therapy | unspecified immune checkpoint inhibitor |
| Indication/Tumor Type | gastrointestinal system cancer |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| MSH6 negative | gastrointestinal system cancer | predicted - sensitive | unspecified immune checkpoint inhibitor | Clinical Study | Actionable | In a retrospective analysis, first-line treatment with immune checkpoint inhibitors (n=30) improved overall response rate (60.7% vs 26.3%; p=0.0005), 24-month progression-free survival (PFS) rate (71.2% vs 7.9%), and median PFS (5.5 months vs not reached; HR=0.21, p<0.0001) compared to first-line chemotherapy (n=103) in patients with mismatch repair-deficient (dMMR) and/or microsatellite instability-high (MSI-H) non-colorectal digestive tract cancers, including pancreatic cancer (PMID: 38537314). | 38537314 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (38537314) | A multicenter study evaluating efficacy of immune checkpoint inhibitors in advanced non-colorectal digestive cancers with microsatellite instability. | Full reference... |